Phase III Trials Show Tozorakimab Reduces COPD Exacerbations with Promising Safety Profile
Phase III trials indicate that tozorakimab effectively reduces COPD exacerbations and shows…
FDA Grants Breakthrough Therapy Designation to Novartis’ Ianalumab for Sjögren’s Disease
The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s…
Boehringer Ingelheim and LEO Pharma Enter Partnership to Commercialize and Further Develop SPEVIGO®
Boehringer Ingelheim and LEO Pharma today announced an exclusive global license and…
Amgen’s Cancer Therapy Meets Key Goal in Phase 3 Gastric Cancer Study
Amgen announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6)…